1-2 of 2
Silvana Lalo Pregja
Close
Sort by
Journal Articles

Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study

Clinical Trials & Observations
Suzanne Lentzsch, Amy O'Sullivan, Ryan C. Kennedy, Mohammad Abbas, Lijun Dai, Silvana Lalo Pregja, Steve Burt, Michael Boyiadzis, G. David Roodman, Markus Y. Mapara, Mounzer Agha, John Waas, Yongli Shuai, Daniel Normolle, Jeffrey A. Zonder
Journal: Blood
Blood (2012) 119 (20): 4608–4613.
https://doi.org/10.1182/blood-2011-12-395715
Published: 2012
Journal Articles

Combination of Bendamustine, Lenalidomide, and Dexamethasone (BLD) in Patients with Refractory or Relapsed Multiple Myeloma Is Safe and Highly Effective: Results of Phase I/II Open-Label, Dose Escalation Study

Suzanne Lentzsch, MD, PhD, Amy O'Sullivan, RN, BSN, Ryan Kennedy, BS, Mohammad Abbas, MD, Navkiranjit Gill, DO, Lijun Dai, MD, PhD, Carrie Andreas, PA-C, Diane Gardner, MSN, CRNP, BC, Silvana Lalo Pregja, MBA, Steve Burt, NP, Robert L. Redner, MD, Robert Volkin, MD, G. David Roodman, MD, PhD, Markus Y. Mapara, MD, PhD, J. Franklin Viverette, MD, Mounzer Agha, MD, John K. Waas, DO, Yongli Shuai, MS, Daniel Normolle, PhD, Jeffrey A. Zonder, MD
Journal: Blood
Blood (2011) 118 (21): 304.
https://doi.org/10.1182/blood.V118.21.304.304
Published: 2011